ReNeuron's PISCES II data published in journal
The PISCES II phase 2a clinical trial was an open-label study in patients living with significant disability resulting from ischaemic stroke.
The global cell-based therapeutics company said that data from the study was originally presented by Professor Keith Muir at the American Heart Association International Stroke Conference 2018 in January 2018.
"We are delighted to see the positive results of the PISCES II clinical trial of our CTX cell therapy candidate for stroke disability published in this highly regarded peer-reviewed journal,” said Olav Hellebø, Chief Executive of ReNeuron Group.
Shares in ReNeuron Group were trading 8.62% higher at 157.5p during Monday trading.]
During the PISCES II trial, 23 stable stroke patients were treated with a single dose of 20 million CTX cells a median of seven months post-stroke.
The greatest improvements on the Modified Rankin Scale (mRS), a measure of disability and dependence, were seen in a pre-specified group of fourteen subjects with residual movement of the affected arm.
The statement noted that out of these patients, 38.5% were responders at six months post treatment and 50% were responders at twelve months.
Data from the PISCES II trial has also been published in a paper online in the Journal of Neurology, Neurosurgery, and Psychiatry, the statement added.
Follow News & Updates from ReNeuron Group here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.